Ligand Pharmaceuticals INC 10-Q quarterly reports

Ligand Pharmaceuticals Inc. announced a significant increase in total revenue and income for the second quarter of 2026, driven by robust royalty growth and strategic financial activities.

Ligand Pharmaceuticals reported a significant increase in Q3 2025 revenue, driven by the Pelthos Transaction and strong royalty growth, alongside new strategic investments and a convertible senior notes offering.

Ligand Pharmaceuticals reported a significant increase in Q2 2025 royalties and total revenue, driven by new financial royalty assets and strong product sales, alongside key strategic investments and divestitures.

Ligand Pharmaceuticals reports a net loss for Q1 2025, driven by a significant increase in research and development expenses, while also announcing a merger agreement for its Pelthos Therapeutics subsidiary.

Ligand Pharmaceuticals' Q3 2024 revenue increased by 58% year-over-year, driven by strong royalty income and milestone payments, despite a decrease in Captisol sales.

Ligand Pharmaceuticals' Q2 2024 results show a significant increase in revenue but also a substantial net loss due to a financial royalty asset impairment, alongside strategic acquisitions and portfolio advancements.

Ligand Pharmaceuticals reported a net income of $86.1 million for the first quarter of 2024, significantly boosted by gains from short-term investments and solid royalty revenue.